Table 3.
Comparison between the LV remodeling and non-LV remodeling group
| No LV remodeling (n = 49) | LV remodeling (n = 43) | T, z or χ2 | P value | |
|---|---|---|---|---|
|
| ||||
| Age (years) | 63.6 ± 8.4 | 62.0 ± 8.8 | 0.838 | .404 |
| Males, n | 40 (81.6%) | 36 (83.7%) | 0.070 | .792 |
| BMI (kg/m2) | 24.80 ± 3.06 | 24.34 ± 2.98 | 0.732 | .466 |
| Hypertension, n | 40 (81.6%) | 28 (65.1%) | 3.240 | .072 |
| Diabetes, n | 14 (28.6%) | 17 (39.5%) | 1.232 | .267 |
| Hyperlipidemia, n | 8 (16.3%) | 3 (7.0%) | 1.902 | .168 |
| COPD, n | 1 (2%) | 1 (2.3%) | 0.009 | .926 |
| History of angina pectoris, n | 42 (85.7%) | 32 (74.4%) | 1.857 | .173 |
| CCS class | 1.63 ± 1.11 | 1.42 ± 1.07 | 0.938 | .351 |
| NYHA class | 1.75 ± 1.00 | 1.95 ± 1.27 | − 0.827 | .411 |
| LVEDVi (ml/m2) | 48.56 ± 7.70 | 100.48 ± 35.51 | − 9.980 | < .001 |
| LVESVi (ml/m2) | 20.27 ± 5.60 | 68.21 ± 37.22 | − 8.908 | < .001 |
| LVEF (%) | 58.76 ± 7.93 | 35.56 ± 13.47 | 10.210 | < .001 |
| STS | 5 (0–8) | 19 (9–29) | − 6.260 | < .001 |
| TPD (%) | 9.43 ± 7.97 | 24.37 ± 15.57 | − 5.897 | < .001 |
| Viable myocardium (%) | 4 (2–7) | 10 (3–23) | − 3.804 | < .001 |
| Scar (%) | 3 (1–6) | 8 (3–13) | − 4.145 | < .001 |
| Reduced thickening segments/normal perfusion segments (%) | 0.00 (0.00–9.55) | 37.5 (20–50) | − 5.842 | < .001 |
| Reduced thickening segments/decreased perfusion segments (%) | 33.33 (0.00–66.67) | 100.00 (66.67–100.00) | − 4.787 | < .001 |
BMI, Body mass index; COPD, chronic obstructive pulmonary disease; CCS, Canadian class classification of angina pectoris; NYHA, New York Heart Association classification of heart failure; LVEDVi, left ventricular end-diastolic volume index; LVESVi, left ventricular end-systolic volume index; LVEF, left ventricular ejection fraction; STS, summed thickening score; TPD, total perfusion deficit